Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

Transplantation, Lung Rejection Clinical Trial

Official title:

A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02614872
• Other study ID #: CT2-LUNG-IV-IL-014
• Status: Completed
• Phase: Phase 2
• Start date: July 26, 2016
• Est. completion date: May 7, 2019

Study information

• Verified date: February 2019
• Source: Kamada, Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the safety and efficacy of intravenous GLASSIA® treatment in lung transplantation.

Description:

There is clinical rationale to advocate the use of AAT(GLASSIA) therapy during episodes of lung inflammation, including acute and chronic rejection. AAT may provide more specifically targeted prevention of pathogenic inflammation, superior to that of general immunosuppressants, with little risk. AAT is the main inhibitor of Neutrophil elastase(NE) in the lower airways and patients with AAT deficiency have low concentrations of the protein in this region of the lung. This explains the proteinase/antiproteinase theory of the development of emphysema in deficient patients in which the amount of elastase released in the lung exceeds the amount of AAT. The net result is persistence of elastase activity leading to lung destruction and the pathological changes of emphysema. Administration of AAT will help to prevent further destruction of the lung architecture and reduce the inflammatory dysregulation that causes pulmonary dysfunction. It is expected that by attacking a specific and previously untreated key component of the pathophysiological cycle of BOS, AAT therapy would decrease the prevalence of BOS in lung transplant recipients and prolong life expectancy of these patients. This will be an open label study in order to ensure safety, in the frame of POC study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 7, 2019
• Est. primary completion date: April 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed and dated informed consent.

2. Age =18 years.

3. Subject is planned to undergo first single or double lung transplant (including heart-lung transplant) as per standard implantation procedure.

Exclusion Criteria:

1. Subject has immunoglobulin A (IgA) deficiency and known anti IgA antibodies.

2. Known history of OR positive serological evidence at the time of screening for hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), Parvovirus B19 (PVB19) or human immunodeficiency virus (HIV) Type 1/2 infection

3. Subjects with a history of severe immediate hypersensitivity reactions, including allergies, anaphylaxis to plasma products or any human proteins of different source.

4. Pregnant or lactating women at entry to study and women of child bearing potential, who are unwilling to agree to continue to use acceptable methods of contraception throughout the study.

5. Presence of psychiatric/ mental disorder or any other medical disorder which might impair the subject's ability to give informed consent or to comply with the requirements of the study protocol.

6. Alcohol abuse or history of alcohol abuse.

7. Illegal drugs.

8. Candidate for organ transplantation other than first lung or heart-lung transplantation

9. Clinically significant bronchial stenosis unresponsive to dilation and/or stenting

10. Participation in another interventional clinical trial within 30 days prior to baseline visit.

11. Inability to attend scheduled clinic visits and/or comply with the study protocol.

12. Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.

Related Conditions & MeSH terms

• Transplantation, Lung Rejection

Intervention

Drug:
• GLASSIA® and Institution standard of care (SOC)
Alpha-1 Antitrypsin (AAT) [GLASSIA®] add-on pharmacotherapy and Institution standard of care (SOC)

Locations

Country	Name	City	State
Israel	Pulmonary Institute - Rabin Medical Center	Petach Tikva

Sponsors (1)

Lead Sponsor	Collaborator
Kamada, Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of subjects experiencing AEs and/or SAEs	Incidence of subjects experiencing causally related AEs and/or SAEs	during the study
Primary	Incidence and rate of Acute Rejection	Incidence and rate of Acute Rejection	per year
Secondary	Annual rate (per subject) of pulmonary infections	Annual rate (per subject) of pulmonary infections	per year
Secondary	Incidence of subjects who develop Bronchiolitis Obliterans	Incidence of subjects who develop Bronchiolitis Obliterans	during the study
Secondary	Changes in Pulmonary Function Test	Changes in Pulmonary Function Test	Change from baseline and overall effect